| 标题 |
[高分]
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:S.-D. Hong; Y.-S. Wang; H.-Y. Zhao; Y.-Y. Zhao; Q.-M. Wang; et al 出版日期:2026 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)